Immunogenicity and its Impact on Benefit/Risk Considerations in the Authorisation of Biopharmaceuticals

Publisher： Bentham Science Publishers

E-ISSN： 2212-3911|5|4|287-292

ISSN： 1574-8863

Source： Current Drug Safety, Vol.5, Iss.4, 2010-10, pp. : 287-292

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Human papillomavirus vaccines: Understanding the benefit-risk

By Neels Pieter  

Annals of Medicine, Vol. 45, Iss. 3, 2013-05 ,pp. : 203-205

Informa Healthcare

Access to resources Recommend Favorite

Benefit–risk assessment of vitamin D supplementation

By Bischoff-Ferrari H.   Shao A.   Dawson-Hughes B.   Hathcock J.   Giovannucci E.   Willett W.  

Osteoporosis International, Vol. 21, Iss. 7, 2010-07 ,pp. : 1121-1132

Springer Publishing Company

Access to resources Recommend Favorite

Benefit–risk management in the age of personalized healthcare

By Forstner Michael  

Personalized Medicine, Vol. 9, Iss. 5, 2012-07 ,pp. : 507-514

Future Medicine

Access to resources Recommend Favorite

Integration of PKPD relationships into benefit–risk analysis

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 5, 2015-11 ,pp. : 979-991

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment

By  

Current Drug Safety, Vol. 5, Iss. 4, 2010-10 ,pp. : 293-307

Bentham Science Publishers

Access to resources Recommend Favorite